Haggerty Stephanie A, Cerulli Jennifer, Zeolla Mario M, Cottrell Jean S, Weck Macary B, Faragon John J
Rite Aid Corporation, Glens Falls, NY, USA.
J Am Pharm Assoc (2003). 2005 Jan-Feb;45(1):17-22. doi: 10.1331/1544345052843020.
To identify the rate of aspirin or antiplatelet/anticoagulant use in persons with diabetes presenting to community pharmacies and determine whether a student pharmacist-driven Target Intervention Program (TIP) could increase the number of eligible persons with diabetes receiving aspirin therapy in accordance with American Diabetes Association (ADA) recommendations.
Unblinded, single intervention.
Eight Community Pharmacy Advanced Practice Experience (CPAPE) sites in New York State.
Persons having prescriptions filled for diabetes medications or supplies who were not receiving antiplatelet/anticoagulant medications.
Assessment sheets were completed by student pharmacists for eligible patients to determine appropriateness for aspirin therapy. Recommendations for aspirin therapy were faxed to physicians when indicated, and physicians responded via fax for aspirin therapy implementation. The student pharmacists contacted patients, informed patients of physician decisions, and provided appropriate counseling.
Number of persons with diabetes currently receiving aspirin or antiplatelet/anticoagulant medications and the number initiated on aspirin as a result of the TIP.
A total of 436 persons with diabetes were identified. Of those contacted, 322 agreed to participate and 31 declined; 228 were taking aspirin or other antiplatelet/anticoagulant agents at baseline. Students completed assessment sheets, which were forwarded to physicians, for 79 subjects potentially eligible to receive aspirin therapy; 65 physician responses were received (82% response rate). Aspirin therapy was initiated in 53 patients (67%).
The TIP enabled CPAPE students to increase aspirin use among eligible persons with diabetes in accordance with ADA guidelines.
确定前往社区药房的糖尿病患者使用阿司匹林或抗血小板/抗凝药物的比例,并确定由学生药剂师推动的目标干预计划(TIP)是否能够按照美国糖尿病协会(ADA)的建议,增加符合条件的糖尿病患者接受阿司匹林治疗的人数。
非盲单干预。
纽约州的8个社区药房高级实践经验(CPAPE)地点。
开具糖尿病药物或用品处方但未接受抗血小板/抗凝药物治疗的患者。
学生药剂师为符合条件的患者填写评估表,以确定是否适合使用阿司匹林治疗。如有必要,将阿司匹林治疗的建议传真给医生,医生通过传真回复以实施阿司匹林治疗。学生药剂师联系患者,告知患者医生的决定,并提供适当的咨询。
目前正在接受阿司匹林或抗血小板/抗凝药物治疗的糖尿病患者人数,以及因TIP计划而开始使用阿司匹林治疗的人数。
共识别出436名糖尿病患者。在被联系的患者中,322人同意参与,31人拒绝;228人在基线时正在服用阿司匹林或其他抗血小板/抗凝药物。学生为79名可能符合阿司匹林治疗条件的受试者填写了评估表,并转发给医生;收到了65份医生回复(回复率82%)。53名患者(67%)开始使用阿司匹林治疗。
TIP计划使CPAPE学生能够按照ADA指南,增加符合条件的糖尿病患者对阿司匹林的使用。